TemanogrelA drug candidate for the prevention and treatment of conditions related to microvascular dysfunction. Temanogrel is an investigational, peripherally acting, and selective 5-HT2A receptor inverse agonist designed to inhibit serotonin (5-HT)-mediated amplification of platelet aggregation and vasoconstriction. Temanogrel is in Phase 2 for microvascular obstruction (MVO) and Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP).
Clinical TrialTemanogrel is an investigational drug and is not currently approved for use by any health authority.
RAYNAUD'S PHENOMENON SECONDARY TO SYSTEMIC SCLEROSIS